Latent Pneumocystis carinii infections were exacerbated in 54 adult male Sprague-Dawley rats by administration of alternating subcutaneous doses of hydrocortisone-21-phosphate and of cortisone acetate three times a week, plus 0.5% chlortetracycline in their drinking water, until death or the termination of the experiment at 120 days. Twenty-eight of the rats were also given pentamidine isethionate (4mg/kg) intramuscularly daily for 14 days. Pentamidine-treated animals that died within the 120 days of the experiment survived longer than control animals. At necropsy, however, every animal in both groups had P. carinii in the lungs. The intensity of the infection was the same in the pentamidine-treated and control groups. Pentamidine isethionate administered in this standard regimen does not exert a significant chemoprophylactic effect against proliferation of P. carinii in rats. The study provides little encouragement for use of pentamidine as a prophylactic agent against P. carinii in high-risk patients.

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/131.3.273DOI Listing

Publication Analysis

Top Keywords

pentamidine isethionate
12
120 days
8
carinii
5
failure pentamidine
4
isethionate provide
4
provide chemoprophylaxis
4
chemoprophylaxis pneumocytis
4
pneumocytis carinii
4
carinii infection
4
rats
4

Similar Publications

Transforming the chemotherapy of human African trypanosomiasis.

Clin Microbiol Rev

January 2025

School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

SUMMARYPrior to 2019, when the orally available drug fexinidazole began its clinical use, the treatment of human African trypanosomiasis (HAT) was complex and unsatisfactory for many reasons. Two sub-species of the parasite are responsible for HAT, namely the rhodesiense form found in East and Southern Africa and the gambiense form found in Central and West Africa. Diseases caused by both forms manifest in two stages: stage 1 before and stage 2 after central nervous system involvement.

View Article and Find Full Text PDF

Background Data on the first-line treatment options for patients with Pneumocystis pneumonia (PCP) without human immunodeficiency virus (HIV) infection are limited. Therefore, we evaluated the outcome of pentamidine compared to trimethoprim-sulfamethoxazole (TMP-SMX) in non-HIV patients with PCP. Methods We used data from the Japanese Diagnosis Procedure Combination Inpatient Database.

View Article and Find Full Text PDF

Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.

PLoS Negl Trop Dis

January 2025

Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China.

Leishmaniasis, a neglected tropical disease caused by Leishmania parasites, continues to pose global health challenges. Current treatments face issues like resistance, safety, efficacy, and cost. This review covers the discovery, mechanisms of action, clinical applications, and limitations of key antileishmanial agents: pentavalent antimonials, amphotericin B, miltefosine, paromomycin, and pentamidine.

View Article and Find Full Text PDF

Leishmaniasis is a neglected disease that remains with a limited number of drugs available for chemotherapy and has an increased drug resistance that affects treatment outcomes. Metal-based drugs such as cyclopalladated complex [Pd(dmba)(μ-N)] (CP2), a Leishmania topoisomerase IB inhibitor involved in calcium dysregulation and mitochondrial dysfunction of the parasite, had been an alternative to outline the appearance of chemoresistance. To identify new molecular targets and point out possible resistance mechanisms, a CP2-resistant Leishmania amazonensis (LaR) was selected by stepwise exposure to increasing drug pressure until a line capable of growth in 13.

View Article and Find Full Text PDF

Background: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP.

Objectives: The objectives of this study are to compare the efficacy (treatment failure and mortality) and tolerability (treatment change) of PCP treatment regimens with a frequentist network meta-analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!